Join to View Full Profile
160 East 34th Street10th FloorNew York, NY 10016
Phone+1 212-731-5820
Fax+1 212-731-5527
Dr. Balar is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
Memorial Sloan Kettering Cancer CenterFellowship, Hematology and Medical Oncology, 2009 - 2012
New York Presbyterian Hospital (Cornell Campus)Residency, Internal Medicine, 2006 - 2009
University of South Florida College of MedicineClass of 2006
Certifications & Licensure
NY State Medical License 2008 - 2023
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012-2013
Clinical Trials
- Neoadjuvant Dose Dense Gemcitabine and Cisplatin (DD GC) In Patients With Muscle-Invasive Bladder Cancer Start of enrollment: 2012 Apr 01
- Phase 2 Study of Docetaxel +/- OGX-427 in Patients With Relapsed or Refractory Metastatic Bladder Cancer Start of enrollment: 2013 Apr 01
- MRI and Bladder Cancer Chemotherapy Start of enrollment: 2013 Aug 01
- Join now to see all
Publications & Presentations
PubMed
- Bempegaldesleukin plus nivolumab in first-line advanced/metastatic urothelial carcinoma: Results from a phase II single-arm study (PIVOT-10).Arlene O Siefker-Radtke, Robert A Huddart, Mehmet A Bilen, Arjun Balar, Daniel Castellano
Urologic Oncology. 2024-10-29 - 4 citationsTROPHY-U-01 Cohort 2: A Phase II Study of Sacituzumab Govitecan in Cisplatin-Ineligible Patients With Metastatic Urothelial Cancer Progressing After Previous Checkpoin...Daniel P Petrylak, Scott T Tagawa, Rohit K Jain, Manojkumar Bupathi, Arjun Balar
Journal of Clinical Oncology. 2024-10-10 - 2 citationsSacituzumab Govitecan Demonstrates Efficacy across Tumor Trop-2 Expression Levels in Patients with Advanced Urothelial Cancer.Yohann Loriot, Arjun V Balar, Daniel P Petrylak, Arash R Kalebasty, Petros Grivas
Clinical Cancer Research. 2024-08-01
Lectures
- Phase 3, randomized, double-blind trial of pembrolizumab plus epacadostat or placebo for cisplatin-ineligible urothelial carcinoma (UC): KEYNOTE-672/ECHO-307.2018 ASCO Annual Meeting - Chicago, Illinois - 06/2/2018
- Atezolizumab (atezo) in first-line cisplatin-ineligible or platinum-treated locally advanced or metastatic urothelial cancer (mUC): Long-term efficacy from phase 2 stu...2018 ASCO Annual Meeting - Chicago, Illinois - 06/2/2018
Press Mentions
Targeted Oncology - FDA Cracks down on Dangling Accelerated Approvals in 2021, Pathway Is ScrutinizedDecember 20th, 2021- Treatment Considerations for Upper Tract Urothelial Carcinoma - Eugene Pietzak and Arjun BalarJune 16th, 2021
- Pembrolizumab in Combination with Gemcitabine and Concurrent Hypofractionated Radiation Therapy as Bladder Sparing Treatment for Muscle-Invasive Bladder Cancer - Arjun BalarJune 10th, 2021
- Join now to see all
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
